The Cardiotoxicity Caused by Anticancer Drugs

References

[1] Albanell, Joan, Jordi Codony, Ana Rovira, Begoña Mellado, and Pere Gascón. 2003. “Mechanism of Action of Anti-HER2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2C4.” Advances in Experimental Medicine and Biology 532: 253–68. doi:10.1007/978-1-4615-0081-0_21.

[2] Albini, Adriana, Giuseppina Pennesi, Francesco Donatelli, Rosaria Cammarota, Silvio De Flora, and Douglas M. Noonan. 2010. “Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention.” Journal of the National Cancer Institute 102(1): 14–25. doi:10.1093/jnci/djp440.

[3] Chen, Carol L, Dipti Gupta, Michael C Kirchberger, and Magid Awadalla. 2018. “Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.” 71(16). doi:10.1016/j.jacc.2018.02.037.

[4] Chianca, Michela, Serena L Abbate, Iacopo Fabiani, Alberto Aimo, Claudio Passino, Antonella Fedele, Carlo Maria Cipolla, et al. 2023. “Expert Opinion on Drug Metabolism & Toxicology Clinical Management of Drug-Induced Cardiotoxicity in Patients with HER-2 + Breast Cancer : Current Recommendations and Future Outlook.” Expert Opinion on Drug Metabolism & Toxicology 19(2): 109–20. doi:10.1080/17425255.2023.2197589.

[5] Costa, Ricardo L.B., and Brian J. Czerniecki. 2020. “Clinical Development of Immunotherapies for HER2+ Breast Cancer: A Review of HER2-Directed Monoclonal Antibodies and Beyond.” npj Breast Cancer 6(1). doi:10.1038/s41523-020-0153-3.

[6] Delveinsight. 2023. “ENHERTU’s Journey in Cancer Treatment and Management.” https://www.delveinsight.com/blog/enhertu-for-cancer-treatment-and-management.

[7] Design, Drug. 2024. “Cardiotoxicity of Anticancer Drugs : Molecular Mechanisms , Clinical Management and Innovative Treatment.” (August): 4089–4116.

[8] Gao, Feiyu, Tao Xu, Fangnan Zang, Yuanyuan Luo, and Defeng Pan. 2024. “Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment.” Drug Design, Development and Therapy 18: 4089–4116. doi:10.2147/DDDT.S469331.

[9] Kim, Dae Won, Kyung Ok Kim, Mike J. Shin, Jung Hee Ha, Sung Wook Seo, Jay Yang, and Francis Y. Lee. 2009. “SiRNA-Based Targeting of Antiapoptotic Genes Can Reverse Chemoresistance in P-Glycoprotein Expressing Chondrosarcoma Cells.” Molecular Cancer 8. doi:10.1186/1476-4598-8-28.

[10] Koukorava, Chrysa, Katie Ahmed, Shrouq Almaghrabi, Amy Pointon, Malcolm Haddrick, and Michael J Cross. 2024. “Anticancer Drugs and of Cardiomyocyte And.” (July): 1–13. doi:10.3389/fcvm.2024.1372817.

[11] Kwok, Cecilia, and Mark Nolan. 2023. “Drugs : Cellular Mechanisms and Clinical Implications.” (September): 1–14. doi:10.3389/fcvm.2023.1150569.

[12] Li, Ang, Sarah B May, Jennifer La, Kylee L Martens, Christopher I Amos, Christopher R Flowers, Nhan V Do, et al. 2023. “Venous Thromboembolism Risk in Cancer Patients Receiving First-Line Immune Checkpoint Inhibitor versus Chemotherapy.” (March): 1214–22. doi:10.1002/ajh.26954.

[13] Morelli, Marco Bruno, Chiara Bongiovanni, Silvia Da Pra, Carmen Miano, Francesca Sacchi, Mattia Lauriola, and Gabriele D’Uva. 2022. “Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.” Frontiers in Cardiovascular Medicine 9(April). doi:10.3389/fcvm.2022.847012.

[14] “No Title.” doi:https://doi.org/10.3389/fcvm.2022.847012.

[15] Raab, G., and W. Eiermann. 2000. “Trastuzumab.” Tagliche Praxis 41(4): 895–98. doi:10.2217/17455057.1.2.161.

[16] Reis-mendes, Ana Filipa, Emília Sousa, Maria De Lourdes Bastos, and Vera Marisa Costa. 2016. “Https://Doi.Org/10.3389/Fcvm.2022.847012.” : 75–90.

[17] Soiza, Roy L., Alison I.C. Donaldson, and Phyo Kyaw Myint. 2018. “Vaccine against Arteriosclerosis: An Update.” Therapeutic Advances in Vaccines 9(6): 259–61. doi:10.1177/https.

[18] Therapy, Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted. “No Title.” doi:Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.

[19] Vallerio, P, A Orenti, F Tosi, M Maistrello, M Palazzini, S Cingarlini, P Colombo, M Bertuzzi, and F Spina. 2022. “AMjor Adverse Cardiovascular Events Associated with VEGF-Targeted Anticancer Tyrosine Kinase Inhibitors : A Real-Life Study and Proposed Algorithm for Proactive Management.” ESMO Open 7(1): 100338. doi:10.1016/j.esmoop.2021.100338.

[20] Varricchi, Gilda, Maria Rosaria Galdiero, Giancarlo Marone, Gjada Criscuolo, Maria Triassi, Domenico Bonaduce, Gianni Marone, and Carlo Gabriele Tocchetti. 2017. “Cardiotoxicity of Immune Checkpoint Inhibitors.” : 1–12. doi:10.1136/esmoopen-2017-000247.

[21] Wang, S. Jennifer, Stephanie K. Dougan, and Michael Dougan. 2023. “Immune Mechanisms of Toxicity from Checkpoint Inhibitors.” Trends in Cancer 9(7): 543–53. doi:10.1016/j.trecan.2023.04.002.

[22] Yin, Qinan, Liuyun Wu, Lizhu Han, Xingyue Zheng, and Lily Wang. 2023. “Immune-Related Adverse Events of Immune Checkpoint Inhibitors : A Review.” (May): 1–17. doi:10.3389/fimmu.2023.1167975.

@article{1707647,
      author = {Aditya Ganesh Bhagwat, Khushal Chaudhari, Prajkta Bhoj},
      title = {The Cardiotoxicity Caused by Anticancer Drugs},
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {8},
      number = {9},
      pages = {1330-1342},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1707647.pdf},
      abstract = {Chemotherapy and targeted therapy have greatly enhanced the prognosis of patients with oncology. Nevertheless, such antineoplastic therapies can also cause unwanted cardiovascular effects, which can be followed by acute or late-onset cardiac dysfunction. These frequent cardiovascular complications, usually called cardiotoxicity, not only can necessitate the adjustment, interruption, or withdrawal of life-saving antineoplastic treatments, with the risk of diminishing their effectiveness, but also can significantly influence the quality of life and survival, irrespective of the oncological prognosis. The development of cardiotoxicity can be dependent on the class, dose, route, and duration of administration of anticancer agents, as well as on individual risk factors. Notably, the cardiotoxic side effects can be reversible, if cardiac function is resumed upon termination of the treatment, or irreversible, in that it is associated with injury and loss of cardiac muscle cells. Subclinical myocardial dysfunction caused by anticancer treatments may also later progress into symptomatic congestive heart failure. Thus, there is a pressing requirement for cardioprotective therapy to decrease the clinical and subclinical cardiotoxicity onset and progression and the acute or chronic manifestation of cardiac injuries. Here in, we review the information about cellular and molecular mechanisms underlying the development of cardiotoxicity from standard classes of chemotherapeutic and targeted therapy agents. In addition, we outline and discuss existing and future approaches to managing the cardiotoxic side effects and cardioprotective preventive measures that would be beneficial to flank anticancer therapies.},
      keywords = {Anticancer, Chemotherapy Cardiotoxicity, Dose},
      month = {March},
  }